Anand Kiran Parikh (then-CEO) purchases 2,806 shares of FTH at $19.76 on day 6 post-listing; holds 817,699 non-derivative shares; company unprofitable ($-170.2M net loss).
Anand Kiran Parikh, who was President and CEO at the time of filing, purchased 2,806 shares at $19.76 on 2026-06-22, six trading days after Faeth Therapeutics' listing. His non-derivative holdings increased to 817,699 shares post-transaction, with additional derivative holdings of 95,739 employee stock options remaining. The purchase occurred in a company with a net loss of $-170,236,000.00 and a market cap of $32,931,232.14. The current price of $24.54 as of 2026-06-24 reflects movement since the trade execution. Investors should note the insider's continued equity exposure through both non-derivative and option holdings in an unprofitable biotech entity during the early post-IPO period.